Endogenous TRAIL/death receptor-mediated caspase-8 and FADD-dependent inflammatory cytokine (e.g., CCL2/MCP-1) secretion in some TRAIL-resistant cancer cells promotes the accumulation of tumor-supportive immune cells in the cancer microenvironment, thereby encouraging cancer growth. This evidence concerns the gene CCL2 and cancer.